Abstract:Glioblastoma (GBM) is one of the most deadly cancers and poorly responses to chemotherapies, such as temozolomide (TMZ). Dysregulation of intrinsic signaling pathways in cancer cells are often resulted by dysregulated tumor suppressive microRNAs (miRNAs). Previously, we found miR-138 as one of tumor suppressive miRNAs that were significantly down-regulated in GBM. In this study, we demonstrated that ectopic over-expression of miR-138 sensitizes GBM cells to the treatment of TMZ and increased apoptotic cell death. Mechanistically, miR-138 directly repressed the expression of Survivin, an anti-apoptotic protein, to enhance caspase-induced apoptosis upon TMZ treatment. Using an intracranial GBM xenograft mice model, we also showed that combination of miR-138 with TMZ increases survival rates of the mice compared to the control mice treated with TMZ alone. This study provides strong preclinical evidence of the therapeutic benefit from restoration of miR-138 to sensitize the GBM tumor to conventional chemotherapy.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to increase the tumor's sensitivity to the chemotherapeutic drug Temozolomide (TMZ) by restoring the expression of microRNA - 138 (miR - 138) in the treatment of Glioblastoma (GBM). Specifically, the study aims to explore whether miR - 138 can enhance the sensitivity of GBM cells to TMZ by down - regulating the expression of Survivin, thereby improving the chemotherapeutic effect. ### Background Glioblastoma is a highly malignant brain tumor and has a poor response to existing treatment methods such as surgery, radiotherapy, and chemotherapy. The median survival time of patients is only about 20 months. Temozolomide is the current standard chemotherapeutic drug for GBM treatment, but its efficacy is limited, partly because the apoptosis - inhibiting mechanism in tumor cells leads to drug resistance to chemotherapeutic drugs. ### Research Objectives 1. **Verify the tumor - suppressing effect of miR - 138**: The research team previously found that miR - 138 is significantly down - regulated in GBM and has a potential tumor - suppressing effect. 2. **Explore the relationship between miR - 138 and Survivin**: Survivin is an anti - apoptotic protein, and the up - regulation of its expression level is related to the drug resistance of GBM to chemotherapeutic drugs. The study aims to verify whether miR - 138 can directly target the 3' untranslated region (3'UTR) of Survivin, thereby down - regulating its expression. 3. **Evaluate the effect of combined treatment of miR - 138 and TMZ**: Through in vitro and in vivo experiments, evaluate whether over - expression of miR - 138 can enhance the sensitivity of GBM cells to TMZ and improve the survival rate of mouse models. ### Main Findings 1. **Over - expression of miR - 138 increases the sensitivity of GBM cells to TMZ**: In vitro experiments show that over - expression of miR - 138 significantly increases the sensitivity of GBM cells to TMZ, manifested as cell proliferation inhibition and increased apoptosis. 2. **miR - 138 directly targets Survivin**: Through Western Blot and dual - luciferase reporter gene experiments, it has been confirmed that miR - 138 can down - regulate the expression of Survivin by directly binding to its 3'UTR. 3. **In vivo experiment verification**: In the xenograft mouse model, the combined treatment of miR - 138 and TMZ significantly improves the survival rate of mice, further supporting the therapeutic potential of miR - 138. ### Conclusion This study provides strong pre - clinical evidence, indicating that restoring the expression of miR - 138 can enhance the sensitivity of GBM to TMZ, thereby improving the chemotherapeutic effect. This finding provides a theoretical basis for the development of new GBM treatment strategies.

MicroRNA-138 Increases Chemo-Sensitivity of Glioblastoma through Downregulation of Survivin

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.

Dnmt1 Mediates Chemosensitivity By Reducing Methylation Of Mirna-20a Promoter In Glioma Cells

MicroRNA-138 Promotes Acquired Alkylator Resistance in Glioblastoma by Targeting the Bcl-2-interacting Mediator BIM.

MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy

Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT

MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2

miR-9-5p Mediates ABCC1 to Elevate the Sensitivity of Glioma Cells to Temozolomide

Hypoxia-Induced miR-137 Inhibition Increased Glioblastoma Multiforme Growth and Chemoresistance Through LRP6

MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma

Mir-126-3p Sensitizes Glioblastoma Cells to Temozolomide by Inactivating Wnt/β-catenin Signaling Via Targeting SOX2

MiR-429 Induces Apoptosis of Glioblastoma Cell Through Bcl-2

Combination of microRNA and suicide gene for targeting Glioblastoma: Inducing apoptosis and significantly suppressing tumor growth in vivo

miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma

A miR-137-XIAP axis contributes to the sensitivity of TRAIL-induced cell death in glioblastoma

MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression.